692737-80-7

Basic information

• Product Name: TKI 258
• Synonyms: Propanoic acid, 2-hydroxy-, coMpd. with 4-aMino-5-fluoro-3-[6-(4;4-AMino-5-fluoro-3-[6-(4-Methyl-1-piperazinyl)-1H-benziMidazol-2-yl]-2(1H)-quinolinone 2-Hydroxypropanoic Acid;Propanoic acid, 2-hydroxy-, coMpd. with 4-aMino-5-fluoro-3-[6-(4-Methyl-1-piperazinyl)-1H-benziMidazol-2-yl]-2(1H)-quinolinone (1:1) ,(lactate salt);4-AMino-5-fluoro-3-(6-(4-Methylpiperazin-1-yl)-1H-benzo[d]iMidazol-2-yl)quinolin-2(1H)-one 2-hydroxypropanoate;4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo-[d]imidazol-2-yl)quinolin-2(1H)-one 2-hyd;CHIR-258, TKI-258;Dovitinib Lactate Salt;4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo-[d]imidazol-2-yl)quinolin-2(1H)-one 2-
• CAS NO: 692737-80-7
• Molecular Formula: C24H27FN6O4
• Molecular Weight: 482.5073832
• Product Categories: Amines;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Antineoplastic
• Mol File: 692737-80-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: TKI 258(CAS DataBase Reference)
• NIST Chemistry Reference: TKI 258(692737-80-7)
• EPA Substance Registry System: TKI 258(692737-80-7)

Safety Data

• Hazardous Substances Data: 692737-80-7(Hazardous Substances Data)

Usage

Chemical Properties

Bright Yellow Solid

Uses

Dovitinib is used in treating melanoma.

Upstream product

• 405169-16-6 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one 
• 849585-22-4 LACTIC ACID 
• 692737-80-7 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one DL-lactic acid salt 
• 23491-48-7 5-(4-methylpiperazine-1-yl)-2-nitroaniline 
• 54998-08-2 4-(4-methylpiperazino)-1,2-diaminobenzene 
• 1635-61-6 5-chloro-2-nitroaniline 
• 402948-37-2 [6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]acetic acid ethyl ester 
• 109-01-3 1-methyl-piperazine 

Downstream Products

• 692737-80-7 dovitinib dilactic acid 

Relevant articles and documents

PREPARATION OF HYDRATED POLYMORPHS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTIC ACID SALT

The present technology provides methods of making anhydrous crystalline Form II and monohydrate crystalline Form S of the lactic acid salt of 4-amino-5-fluoro-3-(6-{4-mefhyipiperazin- 1 -yl)-l H-benzimidazol-2-yl)-1H-quinoiin-2-one.

TREATMENT OF MELANOMA

Methods of treating melanoma include administering a compound of Structure (I), a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a subject. The comp

CRYSTALLINE AND OTHER FORMS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTIC ACID SALTS

The present invention relates to non-hydrate crystalline forms of 4-amino- 5-fluoro-3 -[6-(4-methylpiperazin- 1 -yl)- 1 H-benzimidazol-2-yl] - 1 H-quinolin-2-one lactic acid salts, solid pharmaceutical formulations containing the same and methods of use. The present invention also relates to crystalline hydrates of 4-arnino-5-fiuoro-3-[6-(4- methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one lactic acid salts, pharmaceutical formulations containing the same and methods of use related thereto. The present invention further relates to crystalline solvates of 4-amino-5-fluoro-3-[6-(4- methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one lactic acid salts.